Owners, management and financials
CVR: 44838206
Secondary names: Vectura Fertin Pharma Denmark A/S
Previous names: Vectura Fertin Pharma Denmark A/S
DKK -5,816,709
Gross profit
Net result: DKK -14,892,772
Aspeya Inc. (100%)
CVR · view owners
Christopher Beck Lambert
Board: Helle Egdal Nielsen (chair) and 2 members
CVR · view management
Active
Founded 16 May 2024
CVR · view overview
2 employees
Annual report 2025 · average
Director registered: Christopher Beck Lambert
CVR · 01/06/2025
View the full event history
Aspeya Denmark A/S is a Danish company of the type Aktieselskab based in Vejle, founded in 2024. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Vectura Fertin Pharma Denmark A/S. The management consists of Christopher Beck Lambert. The board consists of Helle Egdal Nielsen (chair), Christopher Beck Lambert and Michael Henrik Thomsen. The company is owned by Aspeya Inc.. According to the 2025 annual report, the company had an average of 2 employees. In 2025, the company reported a gross profit of DKK -5,816,709 and a net result of DKK -14,892,772. Equity in the 2025 report amounted to DKK 2,194,236.
Selskabets formål er at forske, udvikle, fremstille og markedsføre produkter inden for sundhed og velvære samt hermed beslægtet virksomhed, samt at udføre enhver finansiel, kommerciel eller industriel aktivitet, der direkte eller indirekte vedrører formålet.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -5.8 mio. | -14.9 mio. | 7 mio. | 2.2 mio. | 2 |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of Aspeya Denmark A/S is 44838206.
Aspeya Denmark A/S is owned by Aspeya Inc..
The management of Aspeya Denmark A/S consists of Christopher Beck Lambert.
The board of Aspeya Denmark A/S consists of Helle Egdal Nielsen, Christopher Beck Lambert and Michael Henrik Thomsen, with Helle Egdal Nielsen as chair.
In 2025, Aspeya Denmark A/S reported a gross profit of DKK -5,816,709.
Aspeya Denmark A/S had an average of 2 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Aspeya Denmark A/S has published its annual report for 2025. Gross profit came to DKK -5,816,709, and the net result was DKK -14,892,772.
Aspeya Denmark A/S has published its interim report for the period May 16, 2024 – December 31, 2024.
As of June 1, 2025, Christopher Beck Lambert is registered as director of Aspeya Denmark A/S.
As of June 1, 2025, Joel Benjamin Rubenstein has stepped down as director of Aspeya Denmark A/S.
On January 1, 2025, the company changed its name from Vectura Fertin Pharma Denmark A/S to Aspeya Denmark A/S.
As of May 16, 2024, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Aspeya Denmark A/S.
As of May 16, 2024, Christopher Beck Lambert has joined the board of directors of Aspeya Denmark A/S.
As of May 16, 2024, Michael Henrik Thomsen has joined the board of directors of Aspeya Denmark A/S.
As of May 16, 2024, Helle Egdal Nielsen has joined the board of directors of Aspeya Denmark A/S.
As of May 16, 2024, Joel Benjamin Rubenstein is registered as director of Aspeya Denmark A/S.
As of May 16, 2024, is registered as an owner of Aspeya Denmark A/S with an ownership share of 100%.
Aspeya Denmark A/S was founded on May 16, 2024.
Companies in the same industry and area
